News
Is Landstar Stock a Buy After Its Strong Earnings and Revenue Rebound?
Landstar System, Inc. LSTR has a stronger near-term investment case after its second-quarter rebound in revenues, earnings and freight pricing. The stock’s Zacks Rank #1 (Strong Buy), favorable
UGI Q3 Earnings Beat Estimates, Revenues Miss on LPG Weakness
UGI Corporation UGI reported a third-quarter fiscal 2026 adjusted loss of 20 cents per share, which was 42.86% narrower than the Zacks Consensus Estimate of a loss of 35 cents. However, the adjusted
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates
Perrigo PRGO reported second-quarter 2026 All In adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 31 cents. The reported figure declined 12.3% year over year
Atmos Energy Q3 Earnings Beat Estimates, Revenues Increase Y/Y
Atmos Energy ATO reported fiscal third-quarter 2026 earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.34 by 6.7%. The bottom line improved 23.3% from $1.16 in the year-ago
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics, Inc. ANGO offers investors a clear trade-off. Its Med Tech platforms are expanding quickly, but near-term earnings conversion remains weak as tariffs and operating costs absorb part
Symbotic Q3 Earnings Miss Estimates, Revenues Increase Y/Y
Symbotic, Inc. SYM reported mixed third-quarter fiscal 2026 results. Earnings missed the Zacks Consensus Estimate, while revenues surpassed the same.
Quarterly earnings were 9 cents per share
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
AngioDynamics, Inc. ANGO has set an initial fiscal 2027 framework that keeps its Med Tech transformation at the center of the investment case. Faster growth from its priority platforms is expected
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
AngioDynamics, Inc. ANGO shares have gained 33.5% in the past three months, sharply outpacing the broader market and the medical sector. The rally reflects growing interest in the company’s shift
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
Sarepta Therapeutics, Inc. SRPT reported second-quarter 2026 adjusted earnings per share (EPS) of 64 cents, which beat the Zacks Consensus Estimate of 58 cents. However, the reported figure fell 68%
Goodyear Tire & Rubber Q2 Earnings Call Highlights
Key Points
- Interested in The Goodyear Tire & Rubber Company? Here are five stocks we like better.
- Goodyear’s second-quarter sales fell 5% to $4.3 billion, with tire volumes down 4% year over
Reservoir Media Highlights Growth, Catalog Deals as Board Reviews Buyout Proposals
Key Points
- Interested in Reservoir Media, Inc.? Here are five stocks we like better.
- Reservoir Media reported solid fiscal 2026 performance, with revenue rising 11%—including 6% organic
Green Plains Q2 Earnings Call Highlights
Key Points
- Interested in Green Plains, Inc.? Here are five stocks we like better.
- Strong Q2 performance: Green Plains reported adjusted EBITDA of $93.3 million, net income of $67.1 million, and
Gladstone Commercial Q2 Earnings Call Highlights
Key Points
- Interested in Gladstone Commercial Corporation? Here are five stocks we like better.
- FFO increased: Second-quarter FFO and Core FFO each rose to $0.38 per share, up from $0.33 and
Gogo Q2 Earnings Call Highlights
Key Points
- Interested in Gogo Inc.? Here are five stocks we like better.
- Q2 revenue declined modestly to $222.8 million, while Gogo posted a $2 million net loss and adjusted EBITDA fell 13% year
Genmab A/S Q2 Earnings Call Highlights
Key Points
- Interested in Genmab A/S Sponsored ADR? Here are five stocks we like better.
- Genmab raised its 2026 outlook, now forecasting revenue of DKK 4.3 billion–DKK 4.5 billion and operating
Great Elm Capital Group Q2 Earnings Call Highlights
Key Points
- Interested in Great Elm Capital Group, Inc.? Here are five stocks we like better.
- NAV and balance-sheet strength improved: Net asset value rose nearly 3% sequentially to $7.95 per
GoodRx Q2 Earnings Call Highlights
Key Points
- Interested in GoodRx Holdings, Inc.? Here are five stocks we like better.
- GoodRx raised its full-year outlook after reporting Q2 revenue of $200.4 million and adjusted EBITDA of $63.7
Frontdoor Q2 Earnings Call Highlights
Key Points
- Interested in Frontdoor Inc.? Here are five stocks we like better.
- Frontdoor delivered solid Q2 growth: Revenue rose 5% to $645 million, adjusted EBITDA increased 10% to $220
FOX Q4 Earnings Call Highlights
Key Points
- Interested in Fox Corporation? Here are five stocks we like better.
- FOX reported record fiscal 2026 performance, with revenue up 5% to more than $17 billion and EBITDA up 8% to $3.9
Fluence Energy Q3 Earnings Call Highlights
Key Points
- Interested in Fluence Energy, Inc.? Here are five stocks we like better.
- Record demand: Fluence signed $1.44 billion in fiscal Q3 orders, up nearly threefold year over year, while
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines RVMD reported an adjusted loss of $2.34 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.93.
The adjusted figure excluded a
LTM Q2 Earnings Beat on Strong Passenger and Cargo Revenues
LATAM Airlines Group S.A. (LTM) reported second-quarter 2026 earnings of 58 cents per share, which beat the Zacks Consensus Estimate of 14 cents by 314.3%. The bottom line declined 28.4% year over
Should You Buy, Sell or Hold ROOT Stock Post Q2 Earnings?
Root Inc. ROOT posted decent second-quarter 2026 results, with both the top and bottom lines improving year over year. The company witnessed improved in-force premiums and loss ratio.Root is a
Realty Income Q2 Earnings Call Raises 2026 Growth Targets
Realty Income Corporation O raised full-year AFFO and investment targets on its second-quarter 2026 earnings call, citing a broader pipeline and improved funding visibility.
President and CEO Sumit
Copa Holdings Q2 Earnings Miss on Higher Fuel Costs, Revenues Lag
Copa Holdings, S.A. (CPA)reported second-quarter 2026 earnings of $1.67 per share, down 53.9% year over year. The figure missed the Zacks Consensus Estimate of $1.88 by 11.2%, mainly due to a sharp